Rare disease news

FDA approvals, research breakthroughs, clinical trials, and advocacy updates

Curated and summarized by AI for patients and caregivers

🔍
AllDrug approvalsClinical trialsResearchGrants & fundingAdvocacy & policyPipeline
Show:All newsBreaking onlyImportant & breaking
Date:7 days30 days90 daysAll time

3 articles from the last 30 days matching "oral medication"

Clinical trialRSS2 days ago

Patient visits wrap up in Parkinson’s trial of oral bezisterim therapy

A company called Biovie has finished enrolling patients in a study testing a new oral medication called bezisterim for early-stage Parkinson's disease. The medication is being tested as a standalone treatment that patients could take by mouth. The researchers will now analyze all the data collected, with results expected later this year.

WHY IT MATTERSIf bezisterim proves effective in this Phase 2 trial, it could offer Parkinson's patients a new oral treatment option that works alone without requiring combination with other medications.
👁 Watch this spaceParkinson's disease
ResearchRSS3 days ago

SMA patients stick with Evrysdi for years, real-world study finds

A study in Spain found that people with spinal muscular atrophy (SMA) who take Evrysdi, an oral medication, stick with the treatment long-term. All patients in the study continued taking the drug, with some staying on it for over three years. This shows the medication is well-tolerated and patients find it easy to keep using.

WHY IT MATTERSIf you or your child has SMA and are considering Evrysdi, this real-world evidence shows that patients successfully stay on the treatment for years, suggesting it's a practical long-term option with good tolerability.
💬 Ask your doctorspinal muscular atrophy
PipelineRSSMay 7

ALS treatment tazbentetol gets FDA fast track status

The FDA has given fast-track status to tazbentetol, a new oral medication being developed by Spinogenix for ALS (a disease that affects nerve cells that control muscles). Fast-track status means the FDA will review this drug more quickly and the company can talk with FDA regulators more often during development. This designation is given to treatments for serious diseases where there aren't many good options available.

WHY IT MATTERSFast-track designation could bring tazbentetol to ALS patients 1-2 years sooner than standard FDA review timelines, which is critical since ALS progresses rapidly and patients have limited treatment options.
👁 Watch this spaceamyotrophic lateral sclerosis

Get personalized rare disease news

Follow your conditions to see news about the diseases that matter to you — FDA approvals, trial openings, and research breakthroughs.

Create free account →Browse diseases